Humana (HUM) Stock Forecast & Price Target

$245.00

+8.71 (+3.69%)

(As of 09:46 AM ET)

Humana - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold

Based on 24 Analyst Ratings

Sell
1

Hold
17

Buy
6

Based on 24 Wall Street analysts who have issued ratings for Humana in the last 12 months, the stock has a consensus rating of "Hold." Out of the 24 analysts, 1 has given a sell rating, 17 have given a hold rating, and 6 have given a buy rating for HUM.

Consensus Price Target

$331.29
37.30% Upside

According to the 24 analysts' twelve-month price targets for Humana, the average price target is $331.29. The highest price target for HUM is $550.00, while the lowest price target for HUM is $247.00. The average price target represents a forecasted upside of 37.30% from the current price of $245.00.

Get the Latest News and Ratings for HUM and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Humana and its competitors.

HUM Analyst Ratings Over Time

Type	Current Forecast 10/9/23 to 10/8/24	1 Month Ago 9/9/23 to 9/8/24	3 Months Ago 7/11/23 to 7/10/24	1 Year Ago 10/9/22 to 10/9/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	6 Buy rating(s)	9 Buy rating(s)	9 Buy rating(s)	13 Buy rating(s)
Hold	17 Hold rating(s)	12 Hold rating(s)	13 Hold rating(s)	4 Hold rating(s)
Sell	1 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$331.29	$398.70	$409.55	$594.10
Forecasted Upside	37.30% Upside	11.41% Upside	8.04% Upside	18.45% Upside
Consensus Rating	Hold	Hold	Hold	Moderate Buy

The most important AI company you've never heard of (Ad)

Because this small company solves the BIGGEST problem with Nvidia's AI chips. Already, Amazon, Microsoft, Google and others are lining up to get this company's products.

Get the full story on this secret AI company poised for massive growth

HUM Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

HUM Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Humana Stock vs. The Competition

Type	Humana	Medical Companies	S&P 500
Consensus Rating Score	2.21	2.78	2.50
Consensus Rating	Hold	Moderate Buy	Hold
Predicted Upside	40.21% Upside	10,674.28% Upside	8.05% Upside
News Sentiment Rating	Neutral News See Recent HUM News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
10/8/2024	Sanford C. Bernstein 3 of 5 stars		Upgrade	Market Perform ➝ Outperform	$308.00	+30.36%
10/7/2024	TD Cowen 4 of 5 stars	R. Langston Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$402.00 ➝ $261.00	+10.13%
10/7/2024	Jefferies Financial Group 2 of 5 stars		Downgrade	Buy ➝ Hold	$519.00 ➝ $253.00	+5.40%
10/4/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$380.00 ➝ $250.00	+3.31%
10/3/2024	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Hold ➝ Hold	$349.00 ➝ $250.00	+3.70%
10/3/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Tassan Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Neutral	$392.00 ➝ $274.00	+11.93%
Get the Latest News and Ratings for HUM and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Humana and its competitors with MarketBeat's FREE daily newsletter.
10/3/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$400.00 ➝ $280.00	+13.59%
10/2/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	W. Mayo Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
10/2/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Neutral ➝ Underperform	$376.00 ➝ $247.00	+0.44%
10/2/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform	$400.00 ➝ $250.00	+6.05%
10/2/2024	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Fidel Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight	$400.00 ➝ $250.00	-10.53%
10/1/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Neutral ➝ Neutral	$395.00 ➝ $395.00	+30.14%
9/5/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$385.00 ➝ $400.00	+10.97%
8/21/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$332.00 ➝ $396.00	+10.69%
7/15/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Hold ➝ Hold	$355.00 ➝ $400.00	+2.66%
6/24/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Equal Weight	$374.00	+5.21%
5/30/2024	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Ha Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
5/30/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Neutral	$374.00	+8.31%
4/8/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$413.00 ➝ $350.00	+11.78%
4/3/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$450.00 ➝ $385.00	+24.47%
4/2/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Equal Weight ➝ Equal Weight	$356.00 ➝ $310.00	+0.93%
3/22/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Market Perform
3/13/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold
1/26/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$550.00 ➝ $400.00	+10.46%
4/27/2023	SVB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$640.00 ➝ $600.00	+18.70%
2/6/2023	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform	$647.00 ➝ $581.00	+21.91%
2/6/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform	$635.00 ➝ $575.00	+20.65%
11/7/2022	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$547.00 ➝ $647.00	+17.20%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 10:17 AM ET.

Should I Buy Humana Stock? HUM Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, September 30, 2024. Please send any questions or comments about these Humana pros and cons to contact@marketbeat.com.

Humana
Bull Case

Here are some ways that investors could benefit from investing in Humana Inc.:

Humana Inc. has consistently shown strong financial performance, with a solid return on equity of 16.12% and a healthy net margin of 1.53%.
Recent analyst ratings have been positive, with multiple firms upgrading their price targets for Humana Inc., indicating confidence in the company's future growth potential.
Humana Inc. announced a quarterly dividend of $0.885 per share, providing investors with a steady income stream and a dividend yield of 1.11%.
Despite a slight trading dip, Humana Inc.'s stock price remains relatively stable, presenting a potential buying opportunity for investors looking for a stable investment.
With a market capitalization of $38.36 billion, Humana Inc. is a well-established player in the healthcare insurance industry, offering stability and long-term growth prospects.

Humana
Bear Case

Investors should be bearish about investing in Humana Inc. for these reasons:

Humana Inc.'s stock price has experienced fluctuations, with recent trading down 0.4%, indicating potential volatility in the short term.
While the company has a strong financial position, its debt-to-equity ratio of 0.70 may raise concerns for investors wary of high leverage levels.
Analysts have noted that Humana Inc.'s price-to-earnings ratio of 19.95 and price-to-earnings-growth ratio of 2.44 may suggest the stock is currently overvalued in the market.
Despite positive analyst ratings, there are concerns about potential regulatory changes in the healthcare industry that could impact Humana Inc.'s future profitability.
Humana Inc.'s 1-year high of $530.54 and 1-year low of $298.61 indicate significant price volatility, which may not align with the risk tolerance of all investors.

HUM Forecast - Frequently Asked Questions

: According to the research reports of 24 Wall Street equities research analysts, the average twelve-month stock price forecast for Humana is $331.29, with a high forecast of $550.00 and a low forecast of $247.00.
: 24 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Humana in the last twelve months. There is currently 1 sell rating, 17 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" HUM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HUM, but not buy additional shares or sell existing shares.
: According to analysts, Humana's stock has a predicted upside of 35.22% based on their 12-month stock forecasts.
: Over the previous 90 days, Humana's stock had 7 downgrades and 1 upgrade by analysts.
: Humana has been rated by research analysts at Bank of America, Cantor Fitzgerald, Deutsche Bank Aktiengesellschaft, Jefferies Financial Group, JPMorgan Chase & Co., Leerink Partners, Leerink Partnrs, Oppenheimer, Piper Sandler, Royal Bank of Canada, Sanford C. Bernstein, Stephens, TD Cowen, Truist Financial, and UBS Group in the past 90 days.
: Analysts like Humana less than other "medical" companies. The consensus rating for Humana is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how HUM compares to other companies.

Stock Forecasts and Research Tools

Related Companies:

Today's Ratings:

Top Rated Stocks:

More Ratings Tools:

The most important AI company you've never heard of (Ad)

Because this small company solves the BIGGEST problem with Nvidia's AI chips. Already, Amazon, Microsoft, Google and others are lining up to get this company's products.

Get the full story on this secret AI company poised for massive growth

This page (NYSE:HUM) was last updated on 10/8/2024 by MarketBeat.com Staff

From Our Partners